
Nippon India Nifty Pharma ETF
ETFs FundNAV
25.63(-0.20%)Fund Size (CR)
₹1,570.17Expense Ratio
0.21Scheme Type
Passive FundValue Research
-
Min. investment
₹1,000Minimum Additional Investment
₹0Minimum SIP Investment
₹Minimum Withdrawal
₹0Exit Load
0%Return Since Launch
12.28%
Basic Details
Scheme Manager
Jitendra Tolani
Bench Mark
Nifty Pharma TRI
Type
OPEN
Lumpsum Returns
| Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
|---|---|---|---|---|---|---|
| 1 Week | June 18, 2026 | 10282.26 | 2.82% | - | -0.73% | 3/334 |
| 1 Month | May 25, 2026 | 10127.63 | 1.28% | - | -1.35% | 116/332 |
| 3 Month | March 25, 2026 | 11015.14 | 10.15% | - | 5.30% | 82/325 |
| 6 Month | December 24, 2025 | 10996.00 | 9.96% | - | -1.42% | 14/308 |
| 1 Year | June 25, 2025 | 11518.52 | 15.19% | 15.19% | 10.29% | 51/262 |
| 3 Year | June 23, 2023 | 19215.87 | 92.16% | 24.25% | 16.42% | 33/168 |
| 5 Year | - | - | - | - | - | -/- |
| Since Inception | July 6, 2021 | 17787.13 | 77.87% | 12.28% | 16.10% | 140/335 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
| Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
|---|---|---|---|---|---|
| 1 Year | July 1, 2025 | 1,20,000 | 133698.30 | 11.42% | 11.42% |
| 3 Year | July 3, 2023 | 3,60,000 | 456205.02 | 26.72% | 8.21% |
| 5 Year | August 2, 2021 | 5,90,000 | 903483.11 | 53.13% | 8.90% |
| 10 Year | - | - | - | - | - |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Risk Ratios
4.87%
Standard Deviation
1.00%
Beta
1.08%
Sharpe Ratio
0.08%
Treynor's Ratio
-0.25%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
| Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
|---|---|---|---|---|---|
| Sun Pharma.Inds. | 21.42% | 1869418 | 336.35 | Equity | Pharmaceuticals |
| Divi's Lab. | 9.53% | 224373 | 149.59 | Equity | Pharmaceuticals |
| Dr Reddy's Labs | 8.93% | 1075921 | 140.25 | Equity | Pharmaceuticals |
| Cipla | 8.86% | 993316 | 139.16 | Equity | Pharmaceuticals |
| Lupin | 6.18% | 428234 | 97.11 | Equity | Pharmaceuticals |
| Laurus Labs | 5.96% | 686956 | 93.56 | Equity | Pharmaceuticals |
| Torrent Pharma. | 5.19% | 184671 | 81.45 | Equity | Pharmaceuticals |
| Aurobindo Pharma | 4.48% | 493546 | 70.40 | Equity | Pharmaceuticals |
| Glenmark Pharma. | 3.85% | 265843 | 60.48 | Equity | Pharmaceuticals |
| Alkem Lab | 3.62% | 103310 | 56.80 | Equity | Pharmaceuticals |
Peer Comparison
| Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|
List of Schemes under Nippon India Mutual Fund
News
Nippon India Mutual Fund announces change in Exit Load Structure
Nippon India Mutual Fund has announced change in exit load structure under following scheme stands revised with effect from July 01, 2026.Change in Exit Load:
Name of the Scheme Existing Exit Load Revised Exit Load Nippon India Credit Risk Fund 10% of the units allotted shall be redeemed without any exit load, on or before completion of 12 months from the date of allotment of units. Any redemption in excess of such limit in the first 12 months from the date of allotment shall be subject to the following exit load. Redemption of units would be done on First in First out Basis (FIFO): 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units.
Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
25% of the units allotted shall be redeemed without any exit load, on or before completion of 12 months from the date of allotment of units. Any redemption in excess of such limit in the first 12 months from the date of allotment shall be subject to the following exit load. Redemption of units would be done on First in First out Basis (FIFO): 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units.
Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Powered by Capital Market - Live News
Nippon India Mutual Fund announces Appointment of Key Personnel
Nippon India Mutual Fund has announced that Mr. Yoshito Katayama has been appointed as an Associate Director on the Board of NLITL w.e.f. June 04, 2026.Name: Mr. Yoshito Katayama
Age: 60 years
Designation: Associate Director
Qualification: B.A. in Commerce, Hitotsubashi University
Powered by Capital Market - Live News
Nippon India Mutual Fund announces IDCW & Income Distribution cum Capital Withdrawal (IDCW) under its schemes
Nippon India Mutual Fund has announced 10 June 2026 as the record date for declaration of IDCW under the following schemes. The proposed IDCW on the face value of Rs 10 per unit will be:Nippon India Balanced Advantage Fund - Regular Plan ' IDCW 0.2200
Nippon India Balanced Advantage Fund - Direct Plan ' IDCW: 0.2200
Nippon India Multi Asset Allocation Fund - Regular Plan ' IDCW 0.1500
Nippon India Multi Asset Allocation Fund - Direct Plan ' IDCW: 0.1500
Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
June 21, 2021
Total AUM (Cr)
₹1570.17
Nippon India Nifty Pharma ETF is an ETFs Fund-oriented fund from the renowned AMC, Nippon India Mutual Fund. Launched in June 21, 2021, this fund is managed by Jitendra Tolani. With assets under management (AUM) worth ₹1,570.17 (Cr), as of June 25, 2026, Nippon India Nifty Pharma ETF is categorized as a ETFs Fund within its segment. The fund has generated a return of 12.28% since its launch.
The current NAV of Nippon India Nifty Pharma ETF is ₹25.63, as on June 25, 2026. The fund's benchmark index is Nifty Pharma TRI. You can invest in Nippon India Nifty Pharma ETF via both lumpsum and SIP modes. The minimum SIP amount in the fund is - while the minimum lumpsum investment is ₹1,000.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
The fund has generated 24.25% and undefined% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 99.95% in Equity, 0.46% in Debt and -0.41% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 99.97% in Pharmaceuticals & Biotech, 0.16% in Debt, -0.13% in Cash & Others
Mutual Fund Categories
Types of Mutual Funds
Debt Funds
Access debt markets and enjoy interest income from bonds and debentures. Ideal for conservative short-term investors
Hybrid Funds
Enjoy best of both the worlds - equity and debt. Ideal for beginners with medium-term investment horizon
Equity Funds
Invest in large, mid, and small cap sector stocks to enjoy capital appreciation. Ideal for aggressive, long-term investors